A Cochrane review has cast doubt on the efficacy of new Alzheimer’s drugs, noting that these amyloid-targeting biological drugs offer minimal clinical benefits despite high costs and significant risk of severe side effects. The analysis, involving data from 17 clinical trials with over 20,000 participants, found these treatments to be “trivial” in their effects on patients with mild cognitive impairment and mild dementia from Alzheimer’s. The findings have prompted calls for Alzheimer’s research to explore new mechanisms beyond amyloid pathways, with experts like Professors Robert Howard and Paresh Malhotra urging a shift in focus.
In response to these findings, the Czech-based H2 Global Group has proposed a novel approach involving molecular hydrogen therapy to the European Union’s 27 member states. This strategy, outlined in a proposal sent on April 17, 2026, combines molecular hydrogen treatment with VR cognitive rehabilitation, leveraging technology that is already a certified medical device in over 40 European hospitals. The company’s patented method, which targets oxidative stress and neuroinflammation, is backed by Japanese-Czech scientific collaboration and aims to offer a more accessible and cost-effective solution to Alzheimer’s treatment.
The Cochrane review has sparked widespread media attention, with major publications like The Guardian, The New York Times, and the BBC highlighting the limited benefits of the current drugs. The review also pointed out the high annual treatment cost of around €77,000 ($82,000 USD) per patient, which complicates reimbursement processes in various European countries. This has further fueled discussions about the need for alternative therapeutic strategies in addressing dementia.
H2 Global Group’s effort is anchored in scientific research that began with Professor Shigeo Ohta’s 2007 study on hydrogen’s antioxidant properties, with subsequent studies supporting its neuroprotective effects. The company’s clinical study, approved by SÚKL and the Ethics Committee of University Hospital Ostrava, seeks to register a unique medical device using molecular hydrogen. Dr. Milan Krajíček, the firm’s Chief Medical Officer, advocates that their dual approach of addressing brain inflammation and stimulating neuroplasticity through VR holds significant potential.
David Maršálek, CEO of H2 Global Group, emphasizes the urgency and potential of this initiative, envisioning a historic opportunity for the Czech Republic to lead a systemic solution to the dementia epidemic through European collaboration. The company foresees a large-scale clinical study that could provide a safer and more effective alternative for millions of Alzheimer’s patients and their families across Europe. With growing scrutiny over existing treatments, the call for innovative approaches like H2 Global Group’s becomes increasingly pertinent.